Phaseline

Companies › HC Biopharma

HC Biopharma: clinical trials, targets and expected readouts

4 active drug programs in 9 registered trials: 8 Phase 1, 1 Phase 2; Oncology, Other, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HC010
PD-L1 inhibitor
–Phase 2NSCLC; Advanced Solid Tumor; Advanced Solid Tumor CancerDec 2026
HC006–Phase 1Advanced Solid Tumor; Advanced Cancer; Advanced Solid Tumor CancerMay 2027
HC034S
EGFR inhibitor monoclonal antibody (cetuximab biosimilar)
EGFRPhase 1CetuximabJun 2027
HC022–Phase 1Systemic Lupus Erythematosus–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06657703HC022Phase 1Systemic Lupus ErythematosusImmunologyAug 2025
NCT06307925HC010Phase 1Advanced Solid TumorOncologyDec 2025
NCT06304571HC006Phase 1Advanced Solid TumorOncologyMar 2026
NCT07169552HC010Phase 2NSCLCOncologyDec 2026
NCT07381829HC010Phase 1Advanced Solid Tumor CancerOncologyDec 2026
NCT06963814HC006Phase 1Advanced CancerOncologyMay 2027
NCT07813468HC034SPhase 1CetuximabOtherJun 2027
NCT07477743HC010Phase 1Advanced Solid Tumor CancerOncologyDec 2027
NCT07477743HC006Phase 1Advanced Solid Tumor CancerOncologyDec 2027

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical Jiangsu Alphamab Biopharmaceuticals ArriVent BioPharma Wayshine Biopharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.